We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Insights Into Phibro (PAHC) Q4: Wall Street Projections for Key Metrics
Read MoreHide Full Article
Wall Street analysts expect Phibro Animal Health (PAHC - Free Report) to post quarterly earnings of $0.52 per share in its upcoming report, which indicates a year-over-year increase of 26.8%. Revenues are expected to be $361.15 million, up 32.2% from the year-ago quarter.
The current level reflects an upward revision of 1% in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections over this period.
Ahead of a company's earnings disclosure, it is crucial to give due consideration to changes in earnings estimates. These revisions serve as a noteworthy factor in predicting potential investor reactions to the stock. Numerous empirical studies consistently demonstrate a strong relationship between trends in earnings estimate revision and the short-term price performance of a stock.
While investors usually depend on consensus earnings and revenue estimates to assess the business performance for the quarter, delving into analysts' forecasts for certain key metrics often provides a more comprehensive understanding.
That said, let's delve into the average estimates of some Phibro metrics that Wall Street analysts commonly model and monitor.
The combined assessment of analysts suggests that 'Net Sales- Animal Health' will likely reach $274.92 million. The estimate indicates a year-over-year change of +43.6%.
The average prediction of analysts places 'Net Sales- Mineral Nutrition' at $66.40 million. The estimate points to a change of +6.9% from the year-ago quarter.
The consensus estimate for 'Net Sales- Animal Health- Vaccines' stands at $35.23 million. The estimate indicates a year-over-year change of +10.1%.
Analysts forecast 'Net Sales- Animal Health- MFAs and other' to reach $193.28 million. The estimate points to a change of +65.6% from the year-ago quarter.
According to the collective judgment of analysts, 'Net Sales- Animal Health- Nutritional specialties' should come in at $46.42 million. The estimate suggests a change of +8.5% year over year.
The consensus among analysts is that 'Net Sales- Performance Products' will reach $19.83 million. The estimate suggests a change of +1.2% year over year.
The collective assessment of analysts points to an estimated 'Net Sales by Region- Latin America and Canada' of $72.87 million. The estimate points to a change of +3.9% from the year-ago quarter.
Based on the collective assessment of analysts, 'Net Sales by Region- Europe, Middle East and Africa' should arrive at $49.15 million. The estimate suggests a change of +51.7% year over year.
Analysts predict that the 'Net Sales by Region- United States' will reach $213.01 million. The estimate indicates a change of +38.6% from the prior-year quarter.
Analysts expect 'Net Sales by Region- Asia Pacific' to come in at $23.07 million. The estimate indicates a change of +36.4% from the prior-year quarter.
Analysts' assessment points toward 'Adjusted EBITDA- Animal Health' reaching $59.83 million. The estimate is in contrast to the year-ago figure of $41.30 million.
It is projected by analysts that the 'Adjusted EBITDA- Performance Products' will reach $3.38 million. The estimate is in contrast to the year-ago figure of $3.10 million.
Shares of Phibro have demonstrated returns of +7.2% over the past month compared to the Zacks S&P 500 composite's +1.1% change. With a Zacks Rank #2 (Buy), PAHC is expected to beat the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Insights Into Phibro (PAHC) Q4: Wall Street Projections for Key Metrics
Wall Street analysts expect Phibro Animal Health (PAHC - Free Report) to post quarterly earnings of $0.52 per share in its upcoming report, which indicates a year-over-year increase of 26.8%. Revenues are expected to be $361.15 million, up 32.2% from the year-ago quarter.
The current level reflects an upward revision of 1% in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections over this period.
Ahead of a company's earnings disclosure, it is crucial to give due consideration to changes in earnings estimates. These revisions serve as a noteworthy factor in predicting potential investor reactions to the stock. Numerous empirical studies consistently demonstrate a strong relationship between trends in earnings estimate revision and the short-term price performance of a stock.
While investors usually depend on consensus earnings and revenue estimates to assess the business performance for the quarter, delving into analysts' forecasts for certain key metrics often provides a more comprehensive understanding.
That said, let's delve into the average estimates of some Phibro metrics that Wall Street analysts commonly model and monitor.
The combined assessment of analysts suggests that 'Net Sales- Animal Health' will likely reach $274.92 million. The estimate indicates a year-over-year change of +43.6%.
The average prediction of analysts places 'Net Sales- Mineral Nutrition' at $66.40 million. The estimate points to a change of +6.9% from the year-ago quarter.
The consensus estimate for 'Net Sales- Animal Health- Vaccines' stands at $35.23 million. The estimate indicates a year-over-year change of +10.1%.
Analysts forecast 'Net Sales- Animal Health- MFAs and other' to reach $193.28 million. The estimate points to a change of +65.6% from the year-ago quarter.
According to the collective judgment of analysts, 'Net Sales- Animal Health- Nutritional specialties' should come in at $46.42 million. The estimate suggests a change of +8.5% year over year.
The consensus among analysts is that 'Net Sales- Performance Products' will reach $19.83 million. The estimate suggests a change of +1.2% year over year.
The collective assessment of analysts points to an estimated 'Net Sales by Region- Latin America and Canada' of $72.87 million. The estimate points to a change of +3.9% from the year-ago quarter.
Based on the collective assessment of analysts, 'Net Sales by Region- Europe, Middle East and Africa' should arrive at $49.15 million. The estimate suggests a change of +51.7% year over year.
Analysts predict that the 'Net Sales by Region- United States' will reach $213.01 million. The estimate indicates a change of +38.6% from the prior-year quarter.
Analysts expect 'Net Sales by Region- Asia Pacific' to come in at $23.07 million. The estimate indicates a change of +36.4% from the prior-year quarter.
Analysts' assessment points toward 'Adjusted EBITDA- Animal Health' reaching $59.83 million. The estimate is in contrast to the year-ago figure of $41.30 million.
It is projected by analysts that the 'Adjusted EBITDA- Performance Products' will reach $3.38 million. The estimate is in contrast to the year-ago figure of $3.10 million.
View all Key Company Metrics for Phibro here>>>Shares of Phibro have demonstrated returns of +7.2% over the past month compared to the Zacks S&P 500 composite's +1.1% change. With a Zacks Rank #2 (Buy), PAHC is expected to beat the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .